Evidence map›Paper›PMID 37142291›Full record

Trial reportJournal for immunotherapy of cancer2023

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.

Jason A Chesney, Igor Puzanov, Frances A Collichio, Parminder Singh, Mohammed M Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe and 6 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01740297 (Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma), which is not on this map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
17.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01740297 phase1 / phase2completednot on this map

Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma

TypeinterventionalSponsorAmgenRan2013 to 2021Enrolled217ConditionsMelanomaArmsTalimogene laherparepvec, Ipilimumab
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 15 institutions in 4 countries.

Jason A ChesneyJ. Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA jason.chesney@louisville.edu.ORCID 0000-0003-0217-8278
Igor PuzanovRoswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID 0000-0002-9803-3497
Frances A CollichioThe University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Parminder SinghMayo Clinic, Phoenix, Arizona, USA.
Mohammed M MilhemUniversity of Iowa Hospitals and Clinics, Iowa City, lowa, USA.
John GlaspyUniversity of California Los Angeles School of Medicine, Los Angeles, California, USA.
Omid HamidThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, USA.
Merrick RossMD Anderson Cancer Center, Houston, Texas, USA.
Philip FriedlanderMount Sinai School of Medicine, New York, New York, USA.
Claus GarbeUniversity Hospital Tuebingen, Tuebingen, Germany.
Theodore LoganIndiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA.
Axel HauschildDepartment of Dermatology, University of Kiel, Kiel, Germany.
Celeste LebbéUniversité de Paris AP-HP Dermatology CIC Departments, Hôpital Saint-Louis, Paris, France.
Harshada JoshiParexel, Hyderabad, India.
Wendy SnyderAmgen Inc, Thousand Oaks, California, USA.
Janice M MehnertDepartment of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Amgen (United States) · USAngeles Clinic and Research Institute · USChristian-Albrechts-Universität zu Kiel · DEIcahn School of Medicine at Mount Sinai · USIndiana University Health · USMayo Clinic Hospital · USNew York University · USPAREXEL International (India) · INRoswell Park Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversité Paris Cité · FRUniversity of California, Los Angeles · USUniversity of Iowa Hospitals and Clinics · USUniversity of Louisville · USUniversity of North Carolina at Chapel Hill · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
NCI NIH HHS P30 CA086862
6 · The paper itself

Abstract

Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized phase II study. These data provide the longest efficacy and safety follow-up for patients with melanoma treated with a combination of an oncolytic virus and a checkpoint inhibitor.Eligible patients with unresectable stage IIIB‒IV melanoma were randomized 1:1 to receive T-VEC plus ipilimumab or ipilimumab alone. T-VEC was administered intralesionally at 10

Indexed as

Herpesvirus 1, HumanMelanomaOncolytic VirotherapyOncolytic VirusesBiological ProductsHumansIpilimumabBiological ProductsIpilimumabtalimogene laherparepvecimmunotherapymelanomaoncolytic virotherapyoncolytic viruses

Identifiers

PMID37142291
PMCPMC10163510
OpenAlexW4372331756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.